Public Release: 

Cardiovascular disease in females -- new perspectives on lifelong risks

Wolters Kluwer Health

July 2, 2015 - While heart disease is the number one cause of death in both sexes, it poses special considerations in women--with risks often beginning in childhood and changing at different stages of life. Insights on cardiovascular disease (CVD) risk in women and girls throughout the life span are shared in a special symposium feature in the June issue of The American Journal of Medical Sciences (AJMS). The official journal of the Southern Society for Clinical Investigation (SSCI), AJMS is published by Wolters Kluwer.

Two symposium papers seek to increase understanding of CVD risk in female patients: from childhood and adolescence, through the reproductive years, to menopause and beyond. The papers were originally presented at the 2015 Southern Regional Meeting, an annual educational conference sponsored by the SSCI in partnership with other Southern medical organizations.

High Blood Pressure Is Key Risk Factor in Women

Dr. Marie "Tonette" Krousel-Wood of Tulane University, New Orleans, focuses on hypertension (high blood pressure) and health behaviors in women and girls. Despite progress in CVD prevention, rates of coronary heart disease continue to rise in middle-aged women--mirroring the increase in obesity. Although hypertension increases with age in both sexes, the increase is more pronounced in women after menopause. After age 60, the prevalence is higher in women than men.

Low adherence--not taking medications as prescribed--is a major barrier to effective blood pressure control. Poor adherence is a special problem in the growing number of children with hypertension. In adults, adherence may be worse in women than men.

"Despite the negative impact of low adherence on disease control, healthcare providers do not routinely assess adherence in clinical practice," Dr. Krousel-Wood writes. Specific risk factors for low adherence in women may include poor communication with healthcare providers and symptoms of depression.

Recent studies suggest that measuring adherence--asking patients how well they follow their prescription as well as checking pharmacy refill rates--can predict CVD risks in patients with hypertension. Dr. Krousel-Wood concludes, "Together, the objective and self-reported adherence measures provide complementary information that can guide appropriate engagement of patients and providers in the management of high blood pressure and other chronic conditions."

Timing May Affect CVD Prevention with Hormone Therapy

Dr. Suzanne Oparil and colleagues of University of Alabama at Birmingham provide an update on the "timing hypothesis" of estrogen's effects on postmenopausal CVD risk. Some studies have reported that taking estrogen supplements after menopause can reduce CVD risk--yet randomized trials have found no benefit of hormone replacement therapy.

The timing hypothesis suggests that hormone replacement lowers CVD risk if started around or soon after menopause, while later estrogen replacement increases risk. Animal studies suggest that the hormone 17-beta estradiol (E2) delays CVD progression and reduces the response to vascular injury.

In preliminary human studies, responses to E2 are affected by time since menopause--perhaps reflecting changing levels of estrogen receptors. Further studies to clarify the effects of aging on cellular responses to estrogen are needed, and may lead to the development of "estrogen rescue" approaches and new opportunities to using E2 for CVD prevention.

Drs. Krousel-Wood and Oparil hope their reports will further increase attention to CVD risk in female patients at all stages of life. In an introductory editorial, Dr. Daniel Villarreal of SUNY Upstate Medical University writes, "Their insightful analyses establish clear present and future directions for the investigation and management of this ever-growing and challenging problem."

###

Click here to read the special symposium feature.

About The American Journal of the Medical Sciences

Founded in 1820, The American Journal of the Medical Sciences (AJMS) is the official journal of the Southern Society for Clinical Investigation. Regular features include Clinical and Basic Investigation studies, Reviews, Historical Articles, Case-letters, and Images in the Medical Sciences. Other special features include contributions from the University of Texas Southwestern Medical Center, The Art and Sciene of Medical Education, Cardiology Grand Rounds from Vanderbilt University, Clinical Reasoning: A Case-Based Series from Tulane University, Case Report/Focused Reviews, Pathophysiology in Medicine as well as Trainee Research Reports and What's Up Docs? features. The AJMS publishes clinical and basic investigation articles dealing with topics such as infectious disease, rheumatology/immunology, hematology/oncology, cardiology, pulmonology/critical care, gastroenterology, nephrology, neurology and endocrinology.

About the Southern Society for Clinical Investigation

Founded in 1946, the Southern Society for Clinical Investigation (SSCI) is a regional academic society dedicated to the advancement of medically-related research. Its major focus is on encouraging students and postgraduate trainees (residents and fellows) to enter academic medicine and to support junior faculty success in clinical investigation. SSCI members are committed to mentoring future generations of medical investigators and promoting careers in academic medicine. The SSCI is pleased that 2016 will celebrate the Society's 70th anniversary!

About Wolters Kluwer

Wolters Kluwer is a global leader in professional information services. Professionals in the areas of legal, business, tax, accounting, finance, audit, risk, compliance and healthcare rely on Wolters Kluwer's market leading information-enabled tools and software solutions to manage their business efficiently, deliver results to their clients, and succeed in an ever more dynamic world.

Wolters Kluwer reported 2014 annual revenues of €3.7 billion. The group serves customers in over 170 countries, and employs over 19,000 people worldwide. The company is headquartered in Alphen aan den Rijn, the Netherlands. Wolters Kluwer shares are listed on NYSE Euronext Amsterdam (WKL) and are included in the AEX and Euronext 100 indices. Wolters Kluwer has a sponsored Level 1 American Depositary Receipt program. The ADRs are traded on the over-the-counter market in the U.S. (WTKWY).

For more information about our products and organization, visit http://www.wolterskluwer.com, follow @WKHealth or @Wolters_Kluwer on Twitter, like us on Facebook, follow us on LinkedIn, or follow WoltersKluwerComms on YouTube.

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.